Daniel GoldmanSell
CDNA · Transaction Mar 6, 2023 · Filed Apr 17, 2023 · $1,001 to $15,000
NASDAQ NMS - GLOBAL MARKET · CDNA
-1.52% · -$0.6900 · Vol 790.1K
Market closed · last close 4:00 PM ET · price as of 16:00:45 ET
CareDx Inc
Biotechnology
$44.81
Veridion Score
BETAHIGH CONF · 6/6 factorsThu Aug 6 · last completed session · Markets closed · resumes Fri 9:30 ET · CDNA
MethodologyCDNA
CareDx Inc
Thu Aug 6 · last completed session · Markets closed · resumes Fri 9:30 ET
STRONG
Composite intelligence score across six company factor categories. Missing inputs are excluded from the active factor subset.
82/ 100
Veridion Score
STRONG · HIGH confidence
Sovereign · $25/mo
See why this score moved.
- · Factor breakdown with raw signals
- · Day-over-day delta + driver
- · Factor coverage readout
- · Valuation · hype · market flow
- · Pro Chart event markers
- · Score history + alerts
Start Sovereign · $25/mo →
Cancel anytime · or Reserve · $79/mo
Confidence: HIGH · 6/6 factors with data · Thu Aug 6 · last completed session · Markets closed · resumes Fri 9:30 ET
Veridion Score History · 90D
Loading score history
AI Analysis
SovereignWhy is CDNA moving today?
Sovereign unlock connects news, insider activity, analyst moves, and live price action.
About CareDx Inc
SERVICES-MEDICAL LABORATORIESListed since
2014
Employees
765
Country
US
CareDx Inc operates as a precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. It offers testing services, products, and digital solutions along with the pre- and post-transplant patient journey and is a provider of genomics-based information for transplant patients. The Company's commercially available testing services consist of AlloSure Kidney, AlloMap Heart, AlloSure Heart, a dd-cfDNA solution for heart transplant patients, and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. Geographically it generates the majority of its revenue from the United States. The company generates the majority of revenue from the Testing services.
Key statistics
Reported fields plus Veridion-computed history. Unsourced tiles are omitted.
Open
$46.00
Day high
$46.00
Day low
$44.58
Previous close
$45.50
52W high
$47.85
-6.35% from high
52W low
$11.57
92% of range
Market cap
$2.4B
P/E
22.52×
EPS
$1.99
Beta
0.95
Shares out
51.7M
Volume
790.1K
0.65× rel vol
Avg volume
1.2M
VWAP
$45.16
Price history computed in-house
1W
+2.52%
1M
+62.65%
3M
+105.36%
1Y
+271.25%
YTD
+137.85%
SMA 50 $30.33 · above
SMA 200 $21.59 · above
52W position 92%
CDNA overview
Veridion Score
82
6 of 6 factors measured
Congress receipts
5
Daniel Goldman · Sale
13F holders
None on file
Related filings and maps
Public disclosures
Congress activity in CDNA
Official filing ↗
CDNA · Transaction Mar 2, 2021 · Filed Apr 10, 2021 · $15,001 to $50,000
Tom MalinowskiSell
CDNA · Transaction Jan 11, 2021 · Filed Aug 26, 2021 · $1,001 to $15,000
Tom MalinowskiSell
CDNA Common Stock · Transaction Jan 8, 2021 · Filed Aug 26, 2021 · Amount pending receipt enrichment
Tom MalinowskiSell
CDNA · Transaction Jan 6, 2021 · Filed Aug 26, 2021 · $15,001 to $50,000
Federal contracts
CDNA contract awards, year to date.
Public federal awards linked to this ticker.
$491.7K
Refresh interval: 12hSource: Federal contract awards
Department of Veterans Affairs
$491.7K
GENETIC BLOOD TESTING FOR TRANSPLANT PATIENTS (ALLOMAP AND ALLOSURE)
GENETIC BLOOD TESTING FOR TRANSPLANT PATIENTS (ALLOMAP AND ALLOSURE)
Jul 13, 2026
Lobbying spend
CDNA lobbying filings, year to date.
Registered lobbying filings matched to CareDx Inc.
$460.0K
Refresh interval: 12hSource: LDA disclosure filings
Medicare/MedicaidMedicare/Medicaid
Health Issues
Filing
$140.0K
CAREDX INC.
CAREDX, INC.
Apr 20, 2026
Filing
$110.0K
CAREDX INC.
CAREDX, INC.
Jan 20, 2026
Filing
$90.0K
CAREDX INC.
CAREDX, INC.
Jul 20, 2026
Analyst ratings
Sovereign unlock shows live analyst consensus for CDNA.
Options
Sovereign unlock shows live options positioning for CDNA.